Harvard Apparatus Cm (HART) 1.79 $HART Harvard Apparatus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Harvard Apparatus Cm (HART) 1.79 $HART

Harvard Apparatus Regenerative Technology Changes Name to Biostage, Inc. (NASDAQ: BSTG)
PR Newswire - Thu Mar 31, 7:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART) announced today it has changed its corporate name to Biostage, Inc. and will trade under the Nasdaq symbol "BSTG" effective April 1, 2016. Concurrently, the company has launched a new web site www.biostage.com to provide greater clarity and visibility for its technology.
HART: 1.79 (+0.14)

Bioengineered Organ Implant Developer HART Reviews Progress and Q4 2015 Results
PR Newswire - Thu Mar 17, 3:21PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), announced its financial results for the fourth quarter and year ended December 31, 2015 and reviewed its corporate and research progress and plans.
HART: 1.79 (+0.14)

Bioengineered Organ Implant Developer HART Names Accomplished Biotechnology Executive Dr. Blaine McKee to its Board
PR Newswire - Thu Mar 10, 10:06AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced the appointment of Blaine McKee, Ph.D., Senior Vice President and Head of Transactions at Shire plc, to HART's Board of Directors. Dr. McKee has also been named to the Board's Audit Committee, bringing HART back into compliance with the Nasdaq Capital Market's requirement for audit committee composition.
HART: 1.79 (+0.14)

Bioengineered Organ Implant Developer HART To Host Q4 2015 Conference Call Thursday, March 17th at 5:00pm ET
PR Newswire - Tue Mar 08, 7:30AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will announce results of its fourth quarter and year ended December 31, 2015 and provide business commentary after market trading hours on Thursday, March 17, 2016. A conference call to discuss the company's fourth quarter and fiscal year 2015 results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.
HART: 1.79 (+0.14)

Bioengineered Organ Implant Developer HART to Webcast BIO CEO Conference Presentation Tues., Feb. 9th at 8:00 am EST
PR Newswire - Wed Feb 03, 12:34PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that CEO Jim McGorry, will present at the BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 8:00 am EST in New York City. HART's presentation will be webcast live and available for replay.
HART: 1.79 (+0.14)

Bioengineered Organ Implant Developer HART to Webcast Source Capital Disruptive Growth & Healthcare Conference Presentation Wed., Feb. 10th at 3:30 pm EST
PR Newswire - Mon Feb 01, 2:58PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that CEO Jim McGorry will present at the Source Capital Disruptive Growth & Healthcare Conference in New York City on Wednesday, February 10, 2016 at 3:30 pm EST. HART's presentation will be webcast live and available for replay.
HART: 1.79 (+0.14)

HART and Mayo Clinic Confirm Dates for Collaborative Large-Animal Bioengineered Organ Implant Surgeries
PR Newswire - Thu Jan 07, 3:15PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today provided an update on large-animal studies being conducted with its co-development collaborator, Mayo Clinic.
HART: 1.79 (+0.14)

Bioengineered Organ Implant Developer HART to Webcast Biotech Showcase(TM) Presentation Monday, Jan. 11 at 2:00 pm PT
PR Newswire - Wed Dec 30, 8:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, today announced that its CEO Jim McGorry will present at the 8th annual Biotech Showcase conference on Monday, January 11th at 2:00 pm. Pacific Time. Mr. McGorry, Dr. Saverio La Francesca, HART's Chief Medical Officer, and Tom McNaughton, HART's CFO, will also be available for investment community meetings in San Francisco Monday, January 11th through Wednesday, January 13th - contact investor relations (below) to schedule a meeting.
HART: 1.79 (+0.14)

HART Secures Common Stock Purchase Facility with Aspire Capital
PR Newswire - Tue Dec 15, 3:56PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for the esophagus, trachea and bronchus, today announced that it has entered into a two and a half year, $15.0 million common stock purchase agreement with Aspire Capital Fund, LLC, pursuant to which HART has completed an initial sale of 500,000 shares at $2.00 per share. Proceeds from the facility will be used to fund HART's general corporate purposes, including research, development and commercialization activities.
HART: 1.79 (+0.14)

HART's CMO Dr. Saverio La Francesca to moderate panel on "Regenerative Engineering and Bio-Materials" at World Stem Cell Summit Saturday, Dec. 12
PR Newswire - Tue Dec 08, 10:54AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that Executive Vice President and Chief Medical Officer Saverio La Francesca, MD will moderate and speak at the World Stem Cell Summit during a secession entitled "Regenerative Engineering and Bio-Materials" on Saturday, December 12, 2015 at 2:00 p.m. ET. The conference will be held at the Hyatt Regency in Atlanta, GA.
HART: 1.79 (+0.14)

Bioengineered Organ Implant Company HART to Present at RegMed Capital Conference in Atlanta, Friday Dec. 11 at 9:00 am ET
PR Newswire - Thu Dec 03, 11:16AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the RegMed Capital Conference on Friday, December 11, 2015 at 9:00 a.m. ET.. The conference will be held at the Hyatt Regency in Atlanta, GA co-located with the World Stem Cell Summit.
HART: 1.79 (+0.14)

HART Regains Compliance With Nasdaq Minimum Bid Price Listing Rule
PR Newswire - Mon Nov 30, 3:21PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced it has received written notification from The NASDAQ Stock Market that it has regained compliance with the minimum bid price requirements. The letter noted that as a result of the closing bid price of HART's common stock having exceeded $1.00 per share for more than ten consecutive business days, the company has regained compliance and the matter is now closed.
HART: 1.79 (+0.14)

Bioengineered Organ Implant Company HART to Webcast LD Micro Presentation in Los Angeles, Tues. Dec. 1st at 2:30 pm PT
PR Newswire - Wed Nov 25, 12:56PM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today announced that CEO Jim McGorry will present at the LD Micro "Main Event" investor conference on Tuesday, December 1, 2015 at 2:30 p.m. PT. The presentation will be webcast live and posted for replay (link below) for 30 days. Management will also be available at the conference for one-on-one meetings on Wednesday, December 2, 2015. The conference will be held at the Luxe Sunset Bel Air Hotel in Los Angeles, CA.
HART: 1.79 (+0.14)

Health-Care Defies Economic Conditions and Moves to New Highs - Broad Street Alerts
ACCESSWIRE - Tue Nov 17, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / November 17, 2015 / Harvard Apparatus Regenerative Technology Inc. (NASDAQ: HART), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Aeterna Zentaris Inc. (NASDAQ: AEZS), and KaloBios Pharmaceuticals Inc. (NSADQ: KBIO) are four tickers in the health-care space taking part in the bustling M&A activity the sector experienced in the past year. The sector faced recent pressure caused by price gouging and reactions from politicians against 'big pharma' monopolies. However, the health-care sector has thrived nonetheless with in unfavorable economic conditions and has outperformed all other sectors. This presents investors with opportunities for spotting takeover candidates while earning significant returns from holding the large caps as well.
AEZS: 3.44 (+0.07), HART: 1.79 (+0.14), ARNA: 1.68 (+0.01)

HART Reports Q3 Financial Results and Provides Business Update
PR Newswire - Thu Nov 12, 3:05PM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered organ implants for life-threatening conditions, today reported third quarter financial results and provided a business update. Separately this morning, HART reported significant results from research involving its second-generation (Gen2) bioengineered trachea, bronchus and esophagus implants in large animals (Click here for release). HART will host a conference call today at 5:00 pm ET to review its results, progress and outlook (details below).
HART: 1.79 (+0.14)

HART Reports Significant Confirmatory Results for its 2nd Generation Bioengineered Esophagus, Trachea and Bronchus Implants
PR Newswire - Thu Nov 12, 7:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (HART) (Nasdaq: HART), a biotechnology company developing bioengineered implants for life-threatening conditions, today announced significant results - including clear evidence of complete esophageal tissue regeneration - from recently conducted animal research on HART's 2nd Generation (Gen2) bioengineered implant platform. HART will hold a conference call at 5:00 p.m. ET today to discuss these results.
HART: 1.79 (+0.14)

Tissue Engineering Pioneer Dr. Joseph P. Vacanti Agrees to Chair New Scientific Advisory Board for Bioengineered Organ Developer HART
PR Newswire - Wed Nov 11, 10:56AM CST
Harvard Apparatus Regenerative Technology, Inc. ("HART" (NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, announced today that Joseph P. (Jay) Vacanti, M.D., a surgeon and pioneering scientist in the field of tissue engineering, has agreed to serve as Chairman of HART's newly launched Scientific Advisory Board. Final details of Dr. Vacanti's appointment are subject to approval by Massachusetts General Hospital and Partners Healthcare, a non-profit healthcare system and leader in biomedical research founded by Massachusetts General Hospital and Brigham and Women's Hospital. The Advisory Board's role is to provide support and guidance for HART's research and development programs. The Company expects to add three to five additional members to the Advisory Board over the next twelve to eighteen months.
HART: 1.79 (+0.14)

Nasdaq Provides HART With 180-Day Period in Which to Regain Compliance With $1.00 Minimum Closing Bid Price Rule
Marketwired - Tue Nov 10, 3:44PM CST
Harvard Apparatus Regenerative Technology, Inc. ("HART" (NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, announced today that it has received a continued listing deficiency notice from The NASDAQ Stock Market LLC because its share price has not met the $1.00 minimum closing bid price requirement for 30 consecutive business days [Nasdaq Listing Rule 5450(a)(1)]. This notice has no immediate effect on the Company's Nasdaq listing or the trading of its common stock.
HART: 1.79 (+0.14)

Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2015 Financial Results and Investor Teleconference for November 12th
BusinessWire - Fri Oct 30, 2:28PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a biotechnology company developing bioengineered organs for life-threatening conditions, will announce results of its third quarter ended September 30, 2015 and business update after market trading hours on Thursday, November 12, 2015. A conference call to discuss the company's third quarter results and business outlook is scheduled for that same day at 5:00 PM (Eastern Time). On that call, management may respond to questions from the audience on any of a number of topics related to the business, including clinical and preclinical research, operations, plans and outlook.
HART: 1.79 (+0.14)

Harvard Apparatus Regenerative Technology Provides Business Update and Reports Second Quarter 2015 Financial Results
BusinessWire - Thu Aug 13, 3:05PM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a biotechnology company developing bioengineered organs for life-threatening conditions, today provided a business update and reported unaudited financial results for the three months ended June 30, 2015.
HART: 1.79 (+0.14)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 115

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 43

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 55

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 123

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 77

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 114

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading

Top 5 Most Recently Viewed Articles

Anivive's Lab Expansion: Driving Innovation in Veterinary Diagnostics

Updated Category News Views 130

Expanding Horizons in Veterinary Diagnostics Anivive is embarking on an exciting journey as it expands its state-of-the-art laboratory, a move that reflects the soaring demand for its specialized pathology services. This enhancement comes in response to the growing interest in veterinary diagnostics, particularly through its subsidiary, Vidium, known for its leadership in...

Continue Reading
Aurora Chen Joins PBGH as Vice President to Lead Advisory Services

Updated Category News Views 239

Aurora Chen Joins PBGH as Vice President of Advisory Services PBGH, a notable nonprofit coalition, has proudly announced the appointment of Aurora Chen as its Vice President of Advisory Services. Bringing a wealth of experience in the health care and employee benefits sector, Chen is set to lead efforts that expand and enhance the advisory services offered by PBGH. This...

Continue Reading
What Are the Pros and Cons of Using a Financial Planner?

Updated Category Personal Finance Views 654

Are you considering enlisting the help of a financial planner and aren’t sure if it's the right choice for you? Then you need to know about their pros and cons! Financial planners play a vital role in offering you support and guidance with tailor-made plans that help you meet your savings, retirement, or investment goals. We have outlined the pros and cons of a...

Continue Reading
Angel Oak Financial Strategies Trust Announces March 2025 Dividend

Updated Category News Views 113

Introduction to Angel Oak Financial Strategies Income Term Trust Angel Oak Financial Strategies Income Term Trust (FINS) has declared a monthly distribution that investors eagerly anticipate. The closed-end fund listed on the New York Stock Exchange is making headlines as it announces a distribution of $0.109 per share for March. Understanding the mechanics behind such...

Continue Reading
Investors Eye Value Stocks as Federal Reserve Makes Moves

Updated Category News Views 81

Exploring Value Stocks Amid Federal Adjustments Bank of America has underscored three key sectors that stand to gain from the Federal Reserve's unique dual approach of cutting interest rates while profits rise in corporate sectors. This 'rare double whammy of stimulus' could present a significant opportunity for savvy investors keen on value stocks. Key Sector Highlights...

Continue Reading